0.76
+0.0236(+3.22%)
Currency In USD
| Previous Close | 0.73 |
| Open | 0.77 |
| Day High | 0.76 |
| Day Low | 0.73 |
| 52-Week High | 1.81 |
| 52-Week Low | 0.55 |
| Volume | 371,511 |
| Average Volume | 633,625 |
| Market Cap | 97.68M |
| PE | -3.78 |
| EPS | -0.2 |
| Moving Average 50 Days | 0.71 |
| Moving Average 200 Days | 1.11 |
| Change | 0.02 |
If you invested $1000 in Atossa Therapeutics, Inc. (ATOS) 10 years ago, it would be worth $2.68 as of April 26, 2025 at a share price of $0.756. Whereas If you bought $1000 worth of Atossa Therapeutics, Inc. (ATOS) shares 5 years ago, it would be worth $331.67 as of April 26, 2025 at a share price of $0.756.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio
GlobeNewswire Inc.
Apr 22, 2025 12:45 PM GMT
SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States P
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire Inc.
Mar 20, 2025 1:13 PM GMT
Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern TimeSEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
GlobeNewswire Inc.
Mar 11, 2025 12:15 PM GMT
SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced its strategic d